BioVie Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
63.9%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$1.19next fiscal year
Monitoring Framework
Key Performance Indicators
SUNRISE-PD Phase 2 Trial Enrollment Quarterly60.0
ADDRESS-LC Phase 2 Trial Enrollment Quarterly200.0
Cash and Cash Equivalents Quarterly20.5MTarget: Maintain sufficient runway for clinical readouts
Watch Items
- SUNRISE-PD Phase 2 Topline Data ReleaseTrigger: Topline results announcement in Q3 2026Action: Evaluate efficacy of bezisterim (NE3107) monotherapy on motor and non-motor symptoms in early-stage Parkinson's disease.
- ADDRESS-LC Phase 2 Topline Data ReleaseTrigger: Topline results announcement in late summer 2026Action: Assess bezisterim's modulation of inflammatory pathways linked to neurocognitive and neuropsychiatric Long COVID symptoms.
- Capital Raising and Dilution RiskTrigger: Filing of $300 million shelf registration statementAction: Monitor potential equity offerings or strategic partnerships to extend cash runway beyond current clinical trials.
Research as of 20 Jun 2026